Table IV.
Genotype | Treatment | Total mice | Incidence |
|||||
Missing sample | Normal | Mild hyperplasia | Severe hyperplasia | Hyperplasia with dysplasiaa | Carcinoma | |||
B6 | No Zn | 24 | 0 | 0 | 1 (4%) | 19 (79%) | 11 (46%) | 4 (17%) |
Zn | 29 | 1 | 3 (11%) | 17 (61%) | 8 (29%) | 6 (21%) | 0 | |
Fhit−/− | No Zn | 34 | 1 | 4 (12%) | 25 (76%) | 4 (12%) | 7 (21%) | 0 |
Zn | 29 | 0 | 6 (21%) | 18 (62%) | 5 (17%) | 2 (7%) | 0 | |
Fhit−/−Nit1−/− | No Zn | 24 | 2 | 0 | 2 (9%) | 16 (73%) | 8 (36%) | 4 (18%) |
Zn | 26 | 1 | 2 (8%) | 6 (24%) | 17 (68%) | 3 (12%) | 0 | |
Fhit−/−Rassf1a−/− | No Zn | 26 | 0 | 0 | 7 (27%) | 17 (65%) | 7 (27%) | 2 (8%) |
Zn | 27 | 0 | 1 (4%) | 13 (48%) | 12 (44%) | 6 (22%) | 1 (4%) |
The hyperplasia with dysplasia column lists the number of mice with mild or severe hyperplasia, that also exhibited dysplasia. chi-square test showed significant differences between Zn and no Zn treatment for B6 (P = 0.003) and Fhit−/−Nit1−/− (P = 0.002) mice in terms of the number of mice with carcinoma and dysplasia (hyperplasia w dysplasia + carcinoma) versus those without dysplasia (normal + mild + severe hyperplasia—hyperplasia w dysplasia), and the P values for Fhit−/− and Fhit−/−Rassf1a−/− mice were 0.11 and 0.491, respectively.